Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Pacemaker | Case Report

Transvenous endocardial pacing with SelectSecure^™ 3830 lead in pediatric patients: case series of two infants and a literature review

Authors: Chuan Yang, Jing Qi, Mahmood Alam, Deling Zou

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Background

The SelectSecure™ 3830 lead is an innovative, lumenless, and thin active fixed lead with a nonretractable screw-in tip and a diameter of 4.1 Fr, making it the thinnest pacing lead available. Its high anti-extrusion properties and durability have shown favorable outcomes in cardiac pacing, especially in pediatric patients. The superfine design and easy implantation of the lead have rendered it a preferred choice in children, particularly in cases of congenital heart disease.

Case presentation

This case series presents two infant patients who underwent transvenous endocardial pacing using the SelectSecure™ 3830 lead, along with a comprehensive literature review on the topic. The study followed the patients for 5 years and 3 years, respectively, and observed stable pacing parameters, indicating a positive therapeutic outcome and safety.

This article discusses the optimal age and body shape for transvenous lead implantation in infants and highlights the advantages and disadvantages of endocardial and epicardial pacing approaches. Although endocardial pacing offers several benefits such as minimal trauma, short hospital stay, and longer battery life, it may not be suitable for intracardiac shunts, and venous occlusion remains a concern. On the other hand, epicardial pacing may be considered for children with challenging endocardial access but comes with higher risk of lead failure and coronary artery compression.

This study emphasizes the importance of careful follow-up in pediatric patients with pacing, as lead failure can occur in young patients owing to growth and development, leading to syncope and battery depletion. The article also underscores the significance of selecting the appropriate pacing location to minimize the impact of cardiac function, with right ventricular septal pacing emerging as a preferable option.

Conclusions

The SelectSecure™ 3830 lead presents a promising solution for transvenous endocardial pacing in pediatric patients with high degree atrioventricular block and bradycardia, ensuring safe and effective pacing as they grow and develop.

Ng LY, Gallagher S, Walsh KP. Case series of late lead dislodgement of Medtronic SelectSecure 3830 pacing leads in growing paediatric patients. Eur Heart J Case Rep. 2021;5(2):ytaa545. https://doi.org/10.1093/ehjcr/ytaa545.CrossRefPubMedCentralPubMed

Fortescue EB, Berul CI, Cecchin F, Walsh EP, Triedman JK, Alexander ME. Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm. 2004;1(2):150–9. https://doi.org/10.1016/j.hrthm.2004.02.020.CrossRefPubMed

Ergul Y, Yukcu B, Ozturk E, Kafali HC, Ayyildiz P, Ergun S, et al. Evaluation of different lead types and implantation techniques in pediatric populations with permanent pacemakers: single-center with 10 years’ experience. Pacing Clin Electrophysiol. 2021;44(1):110–9. https://doi.org/10.1111/pace.14126.CrossRefPubMed

De Filippo P, Giofrè F, Leidi C, Senni M, Ferrari P. Transvenous pacing in pediatric patients with bipolar lumenless lead: ten-year clinical experience. Int J Cardiol. 2018;255:45–9. https://doi.org/10.1016/j.ijcard.2018.01.007.CrossRefPubMed

Khan A, Zelin K, Karpawich PP. Performance of the lumenless 4.1-Fr diameter pacing lead implanted at alternative pacing sites in congenital heart: a chronic 5-year comparison. Pacing Clin Electrophysiol. 2010;33(12):1467–74. https://doi.org/10.1111/j.1540-8159.2010.02884.x.CrossRefPubMed

Bansal N, Samuel S, Zelin K, Karpawich PP. Ten-year clinical experience with the Lumenless, Catheter-Delivered, 4.1-Fr diameter pacing lead in patients with and without congenital heart. Pacing Clin Electrophysiol. 2017;40(1):17–25. https://doi.org/10.1111/pace.12995.CrossRefPubMed

Zartner PA, Wiebe W, Toussaint-Goetz N, Schneider MB. Lead removal in young patients in view of lifelong pacing. Europace. 2010;12(5):714–8. https://doi.org/10.1093/europace/euq059.CrossRefPubMed

Garnreiter J, Whitaker P, Pilcher T, Etheridge S, Saarel E. Lumenless pacing leads: performance and extraction in pediatrics and congenital heart disease. Pacing Clin Electrophysiol. 2015;38(1):42–7. https://doi.org/10.1111/pace.12508.CrossRefPubMed

Daccarett M, Segerson NM, Bradley DJ, Etheridge SP, Freedman RA, Saarel EV. Bipolar lumenless lead performance in children and adults with congenital heart disease. Congenit Heart Dis. 2010;5(2):149–56. https://doi.org/10.1111/j.1747-0803.2009.00374.x.CrossRefPubMed

10.

Küçük M, Balli S, Karadag H. Experience with implantation of Select Secure(®) leads in paediatric patients. Acta Cardiol. 2023;78(6):665–71. https://doi.org/10.1080/00015385.2022.2051878.CrossRefPubMed

11.

Konta L, Chubb MH, Bostock J, Rogers J, Rosenthal E. Twenty-seven years experience with transvenous pacemaker implantation in children weighing < 10 kg. Circulation: Arrhythmia Electrophysiol. 2016;9(2):e003422.

12.

Antretter H, Colvin J, Schweigmann U, Hangler H, Hofer D, Dunst K, et al. Special problems of pacing in children. Indian Pacing Electrophysiol J. 2003;3(1):23–33.PubMedCentralPubMed

13.

Patsiou V, Haidich AB, Baroutidou A, Giannopoulos A, Giannakoulas G. Epicardial Versus Endocardial Pacing in Paediatric patients with atrioventricular block or sinus node dysfunction: a systematic review and Meta-analysis. Pediatr Cardiol. 2023;44(8):1641–8. https://doi.org/10.1007/s00246-023-03213-x.CrossRefPubMedCentralPubMed

14.

Silvetti MS, Drago F, Di Carlo D, Placidi S, Brancaccio G, Carotti A. Cardiac pacing in paediatric patients with congenital heart defects: transvenous or epicardial? Europace. 2013;15(9):1280–6. https://doi.org/10.1093/europace/eut029.CrossRefPubMed

15.

Odim J, Suckow B, Saedi B, Laks H, Shannon K. Equivalent performance of epicardial versus endocardial permanent pacing in children: a single institution and manufacturer experience. Ann Thorac Surg. 2008;85(4):1412–6. https://doi.org/10.1016/j.athoracsur.2007.12.075.CrossRefPubMed

16.

Song L, Meng Q, Liu C, Wang G, Wang H, Zhou G, et al. Experience of treating congenital complete atrioventricular block with epicardial pacemaker in infants and young children: a retrospective study. BMC Cardiovasc Disord. 2023;23(1):575. https://doi.org/10.1186/s12872-023-03620-1.CrossRefPubMedCentralPubMed

17.

Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK, et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. J Cardiovasc Electrophysiol. 2006;17(7):754–9. https://doi.org/10.1111/j.1540-8167.2006.00489.x.CrossRefPubMed

18.

Vos LM, Kammeraad JAE, Freund MW, Blank AC, Breur J. Long-term outcome of transvenous pacemaker implantation in infants: a retrospective cohort study. Europace. 2017;19(4):581–7. https://doi.org/10.1093/europace/euw031.CrossRefPubMed

19.

Dardari M, Cinteza E, Vasile CM, Padovani P, Vatasescu R. Infective endocarditis among Pediatric patients with prosthetic valves and Cardiac devices: a review and update of recent Emerging Diagnostic and Management Strategies. J Clin Med. 2023;12(15). https://doi.org/10.3390/jcm12154941.

20.

Wilhelm BJ, Thöne M, El-Scheich T, Livert D, Angelico R, Osswald B. Complications and Risk Assessment of 25 years in Pediatric Pacing. Ann Thorac Surg. 2015;100(1):147–53. https://doi.org/10.1016/j.athoracsur.2014.12.098.CrossRefPubMed

21.

Takeuchi D, Tomizawa Y. Pacing device therapy in infants and children: a review. J Artif Organs. 2013;16(1):23–33. https://doi.org/10.1007/s10047-012-0668-y.CrossRefPubMed

22.

Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337–82. https://doi.org/10.1093/europace/eut082.CrossRefPubMed

23.

Kubus P, Materna O, Gebauer RA, Matejka T, Gebauer R, Tláskal T, et al. Permanent epicardial pacing in children: long-term results and factors modifying outcome. Europace. 2012;14(4):509–14. https://doi.org/10.1093/europace/eur327.CrossRefPubMed

24.

Mah DY, Prakash A, Porras D, Fynn-Thompson F, DeWitt ES, Banka P. Coronary artery compression from epicardial leads: more common than we think. Heart Rhythm. 2018;15(10):1439–47. https://doi.org/10.1016/j.hrthm.2018.06.038.CrossRefPubMed

25.

Cantù F, De Filippo P, Gabbarini F, Borghi A, Brambilla R, Ferrero P, et al. Selective-site pacing in paediatric patients: a new application of the Select Secure system. Europace. 2009;11(5):601–6. https://doi.org/10.1093/europace/eup058.CrossRefPubMed

26.

Richardson TD, Himes A, Marshall M, Crossley GH. Rationale for and use of the lumenless 3830 pacing lead. J Cardiovasc Electrophysiol. 2023;34(3):769–74. https://doi.org/10.1111/jce.15828.CrossRefPubMed

27.

Hussain MA, Furuya-Kanamori L, Kaye G, Clark J, Doi SA. The effect of right ventricular apical and Nonapical Pacing on the short- and long-term changes in left ventricular ejection fraction: a systematic review and Meta-analysis of randomized-controlled trials. Pacing Clin Electrophysiol. 2015;38(9):1121–36. https://doi.org/10.1111/pace.12681.CrossRefPubMed

28.

Cano Ó, Andrés A, Alonso P, Osca J, Sancho-Tello MJ, Olagüe J, et al. Incidence and predictors of clinically relevant cardiac perforation associated with systematic implantation of active-fixation pacing and defibrillation leads: a single-centre experience with over 3800 implanted leads. Europace. 2017;19(1):96–102. https://doi.org/10.1093/europace/euv410.CrossRefPubMed

Title: Transvenous endocardial pacing with SelectSecure™ 3830 lead in pediatric patients: case series of two infants and a literature review
Authors: Chuan Yang
Jing Qi
Mahmood Alam
Deling Zou
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Pacemaker
Pacemaker
Pacemaker
Atrioventricular Block
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-024-03820-3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Transvenous endocardial pacing with SelectSecure^™ 3830 lead in pediatric patients: case series of two infants and a literature review

Abstract

Background

Case presentation

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Risk factors and the CCTA application in patients with vulnerable coronary plaque in type 2 diabetes: a retrospective study

Shifting perspectives in coronary involvement of polyarteritis nodosa: case of 3-vessel occlusion treated with 4-vessel CABG and review of literature

Pregnancy related complications in women with hypertrophic cardiomyopathy: a nationwide population-based cohort study

Correction: Days alive and out of hospital for adult female and male cardiac surgery patients: a population-based cohort study

Safety and feasibility of rotational atherectomy (RA) versus conventional stenting in patients with chronic total occlusion (CTO) lesions: a systematic review and meta-analysis

Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page